LivaNova FY Conference Summary Company Overview - **Company**: LivaNova (NasdaqGS:LIVN) - **Industry**: Medical Technology (MedTech) - **Recent Revenue**: Approximately $1.3 billion in the last 12 months as of September 2025 [3] - **Core Businesses**: - Cardiopulmonary: Heart-lung machines, oxygenators, and technologies for open heart surgery, with over 70% market share in open heart procedures globally [3] - Epilepsy: Neuromodulation therapy for drug-resistant epilepsy, transforming the lives of over 175,000 patients [4] Key Points and Arguments Financial Performance - **Growth Metrics**: - 10% organic revenue growth - 17% EPS growth - Over $400 million in adjusted free cash flow [4] - **Strategic Evolution**: Significant portfolio reshaping from 2019 to 2022, divesting low-growth assets to focus on promising early-stage opportunities [5] Market Opportunities - **Epilepsy Market**: - Valued at $700 million, significantly underpenetrated with fewer than 10% of eligible patients receiving non-pharmacotherapy annually [8] - **Cardiopulmonary Market**: - Over $2 billion market, experiencing mid-single-digit growth due to aging population and increased surgical complexity [9] - **Obstructive Sleep Apnea (OSA)**: - Rapidly growing market expected to reach $1 billion, with double-digit growth driven by increased awareness and diagnosis rates [9] - **Difficult-to-Treat Depression (DTD)**: - Potential billion-dollar market opportunity pending CMS reimbursement decision [10] Strategic Focus - **Core Business Strength**: Leadership in epilepsy and cardiopulmonary markets provides a foundation for durable growth and cash generation [7] - **Neuromodulation Expertise**: Leveraging capabilities from epilepsy to enter OSA and DTD markets [10] - **Innovation and Clinical Evidence**: Focus on impactful clinical studies and product innovations to drive market penetration [13] Financial Projections - **Revenue Growth**: - Mid- to high single-digit revenue growth expected in cardiopulmonary business [17] - Mid-single-digit CAGR projected for epilepsy [17] - OSA revenue expected to scale between $200 million and $400 million by 2030 [18] - **Operating Margins**: - Anticipated adjusted operating income margin expansion by over 300 basis points in cardiopulmonary and 200 basis points in epilepsy [17] Reimbursement and Market Access - **Improved Reimbursement**: - Close to 50% increase in reimbursement for VNS Therapy procedures under Medicare, enhancing economic viability for providers [35] - **CORE-VNS Study**: Positive real-world evidence supporting the efficacy of VNS Therapy, expected to change market perceptions and drive penetration [39] Capital Allocation Strategy - **Priorities**: - Continued investment in core epilepsy and cardiopulmonary businesses - Focus on OSA commercialization and infrastructure development - Tuck-in M&A opportunities as a growth tool [32][33] CMS Engagement for DTD - **Current Status**: Collaborative discussions with CMS regarding reimbursement for DTD, with a formal request for reconsideration expected soon [41][42] Additional Important Insights - **Market Penetration Strategies**: Plans to expand penetration in existing accounts and re-engage accounts that exited VNS practice due to unfavorable economics [37] - **PolySync Technology**: New titration algorithm showing promising results, with 8 out of 10 non-responders converting to responders, indicating potential for improved patient outcomes [27] This summary encapsulates the key insights from LivaNova's FY Conference, highlighting the company's strategic direction, market opportunities, financial performance, and future growth potential.